RMD RESMED INC
Surgical & Medical Instruments & Apparatus · NYSE · SEC CIK 943819 · Fiscal year ends 06/30
Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY9.0%
TTM net income YoY10.8%
TTM EPS YoY12.4%
Revenue 3-yr CAGR9.4%
Net income 3-yr CAGR20.7%
Margins
Gross margin61.1%
Operating margin33.0%
Net margin27.8%
FCF margin28.1%
EBITDA margin36.4%
Returns
ROE26.4%
ROA19.3%
ROIC (approx.)27.9%
Asset turnover0.69x
Leverage & solvency
Liabilities / assets27.6%
Debt / equity0.07x
Current ratio2.65x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.11x
Accruals ratio-2.2%
Payout ratio22.4%
Capex / revenue2.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-06-30 | FY20252025-06-30 |
|---|---|---|
| Income statement | ||
| Revenue | $5.65B | $5.15B |
| Cost of revenue | $2.20B | $2.09B |
| Gross profit | $3.45B | $3.05B |
| R&D expense | $378.29M | $331.28M |
| SG&A expense | $1.12B | $993.05M |
| Operating income | $1.89B | $1.69B |
| Pretax income | $1.92B | $1.68B |
| Income tax | $396.12M | $276.84M |
| Net income | $1.52B | $1.40B |
| EBITDA | $2.09B | $1.88B |
| EPS (basic) | 10.47 | 9.55 |
| EPS (diluted) | 10.43 | 9.51 |
| Dividends declared per share | 2.40 | 2.12 |
| Weighted avg. shares (diluted) | 146.05M | 147.34M |
| Balance sheet | ||
| Cash & equivalents | $1.47B | $1.21B |
| Receivables | $1.04B | $939.49M |
| Inventory | $945.80M | $927.71M |
| Current assets | $4.32B | $3.51B |
| PP&E, net | $581.83M | $550.79M |
| Goodwill | $2.91B | $3.05B |
| Intangibles | $452.74M | $464.86M |
| Total assets | $8.97B | $8.17B |
| Current liabilities | $1.40B | $1.02B |
| Short-term debt | $259.95M | $9.90M |
| Long-term debt | $399.42M | $658.39M |
| Total debt | $659.37M | $668.29M |
| Total liabilities | $2.38B | $2.21B |
| Shareholders' equity | $6.59B | $5.97B |
| Net debt | -$809.87M | -$541.16M |
| Shares outstanding | 144.24M | 146.39M |
| Cash flow statement | ||
| Operating cash flow | $1.81B | $1.75B |
| Capital expenditure | $156.28M | $89.86M |
| Free cash flow | $1.65B | $1.66B |
| Investing cash flow | -$545.20M | -$200.04M |
| Financing cash flow | -$1.01B | -$606.25M |
| Depreciation & amortization | $201.34M | $198.47M |
| Stock-based compensation | $104.35M | $91.66M |
| Dividends paid | $349.66M | $310.88M |
| Share buybacks | $700.04M | $300.02M |
Free plan shows the latest 2 periods; Pro shows all 18 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.